Stockscreener 앱 받기
14.02
0.50%
-0.07
전일 마감가:
$14.09
열려 있는:
$14.09
하루 거래량:
1.15M
Relative Volume:
1.09
시가총액:
$11.67B
수익:
$3.85B
순이익/손실:
$667.93M
주가수익비율:
21.34
EPS:
0.657
순현금흐름:
$142.30M
1주 성능:
-1.20%
1개월 성능:
+1.23%
6개월 성능:
-13.30%
1년 성능:
-2.64%
1일 변동 폭
$13.97
$14.16
1주일 범위
$13.64
$14.16
52주 변동 폭
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
명칭
Dr Reddys Laboratories Ltd Adr
전화
-
주소
-
RDY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.02 | 11.73B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Nomura | Buy → Neutral |
| 2024-01-11 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2023-08-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-05-18 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-30 | 개시 | JP Morgan | Underweight |
| 2022-11-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 재개 | BofA Securities | Neutral |
| 2021-07-27 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-09-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-09-18 | 업그레이드 | Investec | Sell → Hold |
| 2020-01-28 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-27 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-09 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-11-04 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | 업그레이드 | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2019-06-20 | 개시 | Deutsche Bank | Hold |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | 업그레이드 | CLSA | Outperform → Buy |
| 2019-01-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | 업그레이드 | CLSA | Underperform → Outperform |
| 2017-07-28 | 다운그레이드 | CLSA | Underperform → Sell |
| 2016-07-27 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2016-07-27 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2016-02-10 | 업그레이드 | Credit Agricole | Underperform → Buy |
| 2015-11-10 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
Dr Reddys Laboratories Ltd Adr 주식(RDY)의 최신 뉴스
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Benzinga
Asian Equities Traded in the US as ADRs Fall in Thursday Trading - 富途牛牛
Asian ADRs Nudge Higher As Tech And Pets Take The Lead - Finimize
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires New Shares in Full Truck Alliance Co. Ltd. Sponsored ADR $YMM - Defense World
Asian ADRs Dip In The US As Volatility Continues - Finimize
Is Zoetis Stock Underperforming the Dow? - Barchart.com
Asian ADRs Kick Off The Week With Broad Gains - Finimize
US Stock Market today: Dow Jones, Nasdaq, S&P 500 open higher over improving Fed rate cut bets — Details here - livemint.com
Vise Technologies Inc. Makes New Investment in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Validea's Top Health Care Stocks Based On Peter Lynch11/17/2025 - Nasdaq
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Migdal Insurance & Financial Holdings Ltd. Sells 20,000 Shares of Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asia’s Biggest US-Listed Stocks Saw Mixed Results Today - Finimize
Fintech ADRs Dropped While Telecoms And Pharma Firmed Up - Finimize
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
L&T, Dr Reddys Labs, Coal India, Varun Beverages — Check Price Target Changes From Analysts - NDTV Profit
Why Dr Reddy’s stock may fall today; buzzing stocks list - BusinessLine
Indian pharma giant says Health Canada rejected its application to make generic semaglutide - The Globe and Mail
Asian ADRs See Mixed Results With Fintech In Focus - Finimize
Dr Reddys ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - NDTV Profit
Dr Reddys Laboratories Ltd Adr (RDY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
1.48%
자본화:
|
볼륨(24시간):